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Abstract
The main physiological regulator of erythropoiesis is the hematopoietic growth factor erythropoietin
(EPO), which is induced in response to hypoxia. Binding of EPO to the EPO receptor (EPO-R), a
member of the cytokine receptor superfamily, controls the terminal maturation of red blood cells. So far,
EPO has been reported to act mainly on erythroid precursor cells. However, we have detected mRNA
encoding both EPO and EPO-R in mouse brain by reverse transcription-PCR. Exposure to 0.1% carbon
monoxide, a procedure that causes functional anemia, resulted in a 20-fold increase of EPO mRNA in
mouse brain as quantified by competitive reverse transcription-PCR, whereas the EPO-R mRNA level
was not influenced by hypoxia. Binding studies on mouse brain sections revealed defined binding sites
for radioiodinated EPO in distinct brain areas. The specificity of EPO binding was assessed by
homologous competition with an excess of unlabeled EPO and by using two monoclonal antibodies
against human EPO, one inhibitory and the other noninhibitory for binding of EPO to EPO-R. Major
EPO binding sites were observed in the hippocampus, capsula interna, cortex, and midbrain areas.
Functional expression of the EPO-R and hypoxic upregulation of EPO suggest a role of EPO in the
brain.
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ABSTRACT The main physiological regulator of eryth-
ropoiesis is the hematopoietic growth factor erythropoietin
(EPO), which is primarily produced in the kidney of adult
mammals and is induced in response to hypoxia. Binding of
EPO to the EPO receptor (EPO-R), a member of the cytokine
receptor superfamily, controls the terminal maturation of red
blood cells. So far, EPO has been reported to act mainly on
erythroid precursor cells. However, we have detected mRNA
encoding both EPO and EPO-R in mouse brain by reverse
transcription-PCR. Exposure to 0.1% carbon monoxide, a
procedure that causes functional anemia, resulted in a 20-fold
increase of EPO mRNA in mouse brain as quantified by
competitive reverse transcription-PCR, whereas the EPO-R
mRNA level was not influenced by hypoxia. Binding studies on
mouse brain sections revealed defined binding sites for ra-
dioiodinated EPO in distinct brain areas. The specificity of
EPO binding was assessed by homologous competition with an
excess of unlabeled EPO and by using two monoclonal anti-
bodies against human EPO, one inhibitory and the other
noninhibitory for binding of EPO to EPO-R. Major EPO
binding sites were observed in the hippocampus, capsula
interna, cortex, and midbrain areas. Functional expression of
the EPO-R and hypoxic upregulation ofEPO suggest a role of
EPO in the brain.
Erythropoietin (EPO) is a 30.4-kDa glycoprotein which rep-
resents the major regulator of erythropoiesis (reviewed in refs.
1-3). The main site of EPO production switches during
development from the fetal liver to the adult kidney. Fibro-
blast-like type I interstitial cells have been identified as the
EPO-producing cell population in the kidney (4, 5). In the
liver, both a subset of hepatocytes and the nonparenchymal Ito
cells, also known as fat-storing or perisinusoidal cells, have
been reported to be the source ofEPO production (6, 7). EPO
gene expression is regulated in an oxygen-dependent manner:
hypoxic exposure results in elevated EPO production in mam-
mals and in the EPO-producing human hepatoma cell lines
HepG2 and Hep3B (1-3). Binding of EPO to the EPO
receptor (EPO-R), a member of the cytokine receptor super-
family (8), leads to enhanced red blood cell production by
suppressing programmed cell death of erythroid progenitor
cells (reviewed in ref. 9). So far, EPO has been shown to act
mainly on erythroid cells. However, apart from its key function
in erythropoiesis, EPO may also influence the functional
behavior of nonerythroid cells: EPO might have mitogenic and
chemotactic effects on endothelial cells (10) and fetal liver
stromal cells (11), both cell types harboring the EPO-R (12, 11).
Stimulation of differentiation and increased DNA synthesis in
response to EPO has been observed in megakaryocytes in vitro
(13, 14), which is consistent with functional expression ofEPO-R
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on those cells (15). In addition, EPO showed neurotrophic effects
on cultured embryonal neurons and supported survival of injured
rat neurons in vivo (16). Furthermore, in vitro expression of the
EPO-R has been detected in rat PC12 cells, an adrenal medullary
pheochromocytoma-derived cell line which displays some neu-
ronal properties in culture; the EPO-R cDNA sequence from
PC12 cells was found to be identical to the one from erythroid
cells (17).
Assuming that EPO-dependent modulation of neuronal
cells in culture reflects the in vivo situation in the brain, one
would expect local EPO expression in this organ since kidney-
derived EPO is unlikely to cross the blood-brain barrier.
Indeed, accumulation of EPO mRNA in the brain of hypoxic
rats has been observed by a ribonuclease protection assay (18).
Furthermore, human tumors of the central nervous system
such as meningioma (19) and cerebellar hemangioblastoma
(20), both associated with secondary erythrocytosis, have been
found to synthesize EPO. In the present work, we quantified
the hypoxic upregulation of EPO mRNA in the murine brain
and localized specific EPO binding sites in defined areas of the
brain by in situ binding studies using radioiodinated EPO.
MATERIALS AND METHODS
Animals. Mice were bred in our conventional animal facil-
ities. EPO production was induced by exposing the mice to
0.1% carbon monoxide for 4 hr (21). Blood was collected from
stimulated and control animals and, after perfusion and
decapitation, brain and kidney were removed and frozen in
liquid nitrogen. Serum EPO concentrations were measured by
RIA (22). Total RNA from brain and kidney was isolated with
the RNAzol kit (Cinna/Biotecx, Houston, TX). Resuspended
total RNA was quantified by spectrophotometric absorbance at
260 nm and tested for integrity by agarose gel electrophoresis.
Reverse Transcription (RT)-PCR. Total RNA (1 ,ug) from
brain, kidney, and murine erythroleukemia (MEL) cells was
reverse-transcribed with Promega's RT system. One-seventh
of the reaction mixture was used as template for PCR ampli-
fication of either EPO or EPO-R cDNA with the primers
5'-ATCTGCGACAGTCGAGTTCT-3' (sense) and 5'-
GTATCCACTGTGAGTGTTCG-3' (antisense), located in
exon 2 and exon 5, respectively, of the murine EPO gene, and
5'-GGACACCTACTTGGTATTGG-3' (sense) and 5'-
GACGTTGTAGGCTGGAGTCC-3' (antisense), located in
exon 8 and the 3' untranslated region, respectively, of the
murine EPO-R gene (23). RT-PCR products were 395 bp for
EPO and 452 bp for EPO-R. EPO mRNA was quantified by
competitive RT-PCR (24). The competitor EPO template was
obtained by a 1.4-kb Sca I-Sma I deletion of a mouse genomic
EPO clone which, after amplification with the same primer set,
resulted in a 492-bp fragment (H.H.M., R.H.W., L.A.R., and
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M.G., unpublished work). Varying amounts of synthetic RNA
competitor template were added to the total RNA samples
prior to RT-PCR. The relative amount of amplified target
cDNA versus competitor cDNA was quantitated by visual
inspection of ethidium bromide-stained agarose gels of the
amplified products.
'2'I-EPO Binding on Slide-Mounted Sections. Anesthetized
adult male mice were perfused with 7 ml of ice-cold 0.9% NaCl
through the left ventricle. The brain and the quadricipital
muscle were removed and washed in ice-cold phosphate-
buffered saline for 15 min. Subsequently, the tissues were
frozen in liquid nitrogen-cooled isopentane for 20 min and
transferred quickly into a precooled cryocut chamber (- 17°C).
After drying, the brain and the skeletal muscle were mounted
on precooled chucks and embedded. The tissues were then cut
in 17-,um sections at - 17°C, thaw-mounted on precooled
gelatin-coated slides, washed twice with phosphate-buffered
saline for 10 min, and dried with an air stream (25). Nonspe-
cific binding sites were blocked by preincubation with a protein
mixture consisting of 0.5 mM ribonuclease A (Sigma), 1 mM
trypsin inhibitor (Sigma), 0.05 mM wheat germ agglutinin
(Boehringer Mannheim), and 1 mM ovalbumin (Sigma). After
the preincubation solution was removed, 1251-labeled recom-
binant human EPO (specific activity: 300-900 Ci/mmol; Am-
ersham; 1 Ci = 37 GBq) was dissolved in phosphate-buffered
saline containing 0.1% bovine serum albumin and added to the
slices, which subsequently were incubated for 90 min at room
temperature. The concentration of the 125I-EPO in the incu-
bation solution was 400-500 pM, close to the Kd value found
in erythroid colony-forming-unit cells (26). Following incuba-
tion, the slices were washed twice in cold phosphate-buffered
saline for 10 min, dipped in water, and dried in an air stream
in order to prevent diffusion of the reversibly bound ligand.
Dried slices were exposed to Hyperfilm 3H (Amersham) for 10
to 14 days at 4°C. In competition experiments, unlabeled
recombinant human EPO (Boehringer Mannheim) was mixed
at 1000-fold molar excess with 125I-EPO prior to incubation.
Preincubation of 125I-EPO with monoclonal antibodies
(mAbs) was performed in a molar ratio of 1:100 at 37°C for 60
min in a rotary shaker (150 rpm).
RESULTS AND DISCUSSION
Transcripts encoding EPO and EPO-R were found in total
brain RNA. Stimulation of EPO production in 8-week-old
mice (n = 9) was achieved by exposing the animals to an
atmosphere containing 0.1% carbon monoxide, a procedure
that causes functional anemia. The brains of stimulated ani-
mals were removed after in vivo perfusion, and total RNA
isolated from individual mice was analyzed for the presence of
EPO and EPO-R mRNA. RT-PCR analysis revealed that both
genes are transcribed in the mouse brain (Fig. 1). The identity
of the amplified products was confirmed by restriction frag-
ment length analysis and Southern blotting.
These findings encouraged us to test whether EPO gene
expression in brain is regulated in an oxygen-dependent man-
ner as it is in kidney and liver. To this end, we quantified
specific EPO mRNA in the brain of carbon monoxide-exposed
mice and unstimulated control animals by means of compet-
itive RT-PCR. Hypoxic stimulation of mice was confirmed by
a 40-fold increase of immunoreactive serum EPO concentra-
tions as shown by RIA (Fig. 2A). The amount of specific EPO
mRNA isolated from brain of unstimulated control mice was
1-2 fg/,ug of total RNA; exposure to carbon monoxide resulted
in an =20-fold accumulation of EPO mRNA (Fig. 2B), indi-
cating that the gene encoding EPO is capable of responding to
hypoxia in some cerebral cells. In comparison, the renal EPO
mRNA concentration of normoxic mice was about 10 fg/,ug of
total RNA and showed an up to 200-fold increase in stimulated
kidneys (H.H.M., R.H.W., L.A.R., and M.G., unpublished
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FIG. 1. Expression of EPO and EPO-R mRNA in brain from
8-week-old mice. RT-PCR analysis of EPO mRNA (lanes 2-5) and of
EPO-R mRNA (lanes 6-9) was performed with 1 ,ug of total RNA
from brain (lanes 3 and 7) and kidney (lane 2) of a carbon monoxide-
stimulated, perfused mouse (positive control for EPO mRNA) and
from MEL cells (lane 6) (positive control for EPO-R mRNA; ref. 27).
Two negative controls were carried out for each RT-PCR set by
omitting either reverse transcriptase (lanes 4 and 8) or total RNA
(lanes 5 and 9). DNA migration of a 100-bp DNA ladder (Pharmacia)
is indicated (lane 1).
work). This observation implies that the adaptive molecular
mechanisms in response to hypoxia in the brain correspond to,
but might not be identical with, the oxygen-dependent regu-
lation of the EPO gene in kidney and liver. Furthermore,
assuming that the EPO mRNA level correlates with the
amount of EPO protein production, one would expect a
modest increase in brain EPO compared with renal EPO after
hypoxic induction. Since EPO is unlikely to cross the blood-
brain barrier, this difference might represent an adaptation to
the different supply mechanisms of EPO to its target organs:
while kidney-derived EPO is delivered into the blood for
transport to the bone marrow, brain-derived EPO is restricted
to act locally in this organ, presumably in a paracrine fashion.
Specific binding sites for EPO in brain tissue were visualized
by binding studies in which 125I-labeled recombinant human
EPO was incubated with slide-mounted unfixed brain sections
of perfused 8-week-old mice. Binding of 125I-EPO was ob-
served in distinct areas of the brain as shown in frontal sections
(Fig. 3A). Competition of 125I-EPO with a 1000-fold molar
excess of unlabeled EPO resulted in a strong decrease of the
signal (Fig. 3B) compared with the adjacent brain section
exposed only to 125I-EPO (Fig. 3A), indicating the specificity
of binding sites for EPO in the brain. These results were
confirmed by using two mAbs raised against recombinant
human EPO which either inhibit (mAb E14) or do not inhibit
(mAb D7) binding of EPO to the EPO-R (28). The two mAbs
have comparable affinities for human EPO (Kd of 0.3 nM).
Preincubation of 125I-EPO with mAb E14 strongly inhibited
binding to EPO-R, thereby abolishing the autoradiographic
signal compared with an adjacent control brain slice (Fig. 3 C
and D). In contrast, binding of 125I-EPO to EPO-R was not
influenced after preincubation with the noninhibitorymAb D7
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FIG. 2. Quantification of serum EPO protein and brain EPO
mRNA. (A) Serum EPO levels from three carbon monoxide-
stimulated (gray bars) and three control mice (black bars) were
measured by RIA. (B) EPO mRNA in brain of these animals was
quantified by competitive EPO RT-PCR.
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FIG. 3. Specific binding of 125I-EPO to mouse brain sections.
Frontal brain section of an 8-week-old mouse incubated with 1251-EPO
(A) and adjacent section incubated with 125I-EPO and a 1000-fold
molar excess of unlabeled EPO (B). Control frontal sections (C and E)
and adjacent sections incubated with 125I-EPO and either the inhib-
itory mAb E14 (D) or the noninhibitory mAb D7 (F). Since we could
not detect muscular EPO-R transcripts by RT-PCR, skeletal muscle
sections were used as negative controls (not shown).
(Fig. 3 E and F). In an additional control experiment, we
observed that preincubation with a nonrelated mAb raised
against rat renin did not alter the binding of EPO to EPO-R
(data not shown). In contrast to EPO, hypoxic induction of
EPO-R in brain was not detected either by RT-PCR analysis
or by radioligand binding studies on brain sections from
hypoxic mice (data not shown).
125I-EPO bound to defined areas in the brain (Fig. 4). The
most intense staining was visible in capsula interna, corpus
callosum, fimbria hippocampus, zona incerta, alveus (not
shown), and mamillothalamic tract (not shown). Intermediate
FIG. 4. Specific 1251-EPO binding sites in two frontal mouse brain
sections. The distance between the frontal section (A) and the dorsal
section (B) is 200 ,um. The sections were prepared and processed as
described in Fig. 3. Nomenclature (29): CPu, caudatoputamen; co,
cerebral cortex; cc, corpus callosum; fi, fimbria hippocampus; GP,
globus pallidus; HI, hippocampus; ic, internal capsule; LH, lateral
hypothalamic area; zi, zona incerta.
autoradiographic staining was also observed in neocortical
regions such as the outer cortical layers and in the hippocam-
pus, which is an archaeocortical area. The hippocampus
showed very distinct staining: while staining of the cellular
layers containing pyramidal cells was intense, the labeling of
adjacent layers containing fiber systems was decreased. Fur-
ther staining was visible in brainstem, mesencephalon, and
lateral posterior thalamic nuclei (all three areas not shown),
caudatoputamen, globus pallidus, and lateral hypothalamus.
Autoradiographic staining of the cerebellum was dependent
on the sectioning level: binding of 125I-EPO was observed in
sections containing the granular layer but was not detectable
in other cerebellar areas. Figs. 3 and 4 reveal that the main
125I-EPO binding site is the white matter, which consists of
myelinated nerve fibers, oligodendrocytes, and fibrous astro-
cytes. A report showing functional EPO-R expression in
cultured cells with neuronal characteristics (17) suggests that
axons might be one possible candidate carrying the EPO-R.
Furthermore, expression of EPO-R reported in mouse em-
bryonic stem cells (30) and in the mouse postimplantation
embryo (31) has interesting implications for the role of EPO
in early development, including hematopoiesis and neurogen-
esis. This notion is further supported by a report describing the
tissue-specific mRNA expression of the endogenous EPO-R
gene and the human EPO-R transgene in the brain of trans-
genic mouse embryos (32).
Multiple EPO- and non-EPO-producing cell lines of various
species were found to have the capability of sensing oxygen
tensions and responding to hypoxia, implying that oxygen
sensing is a widespread mechanism in mammalian cells (33,
34). While this manuscript was in preparation, Masuda et at
(35) reported the partial purification of biologically active EPO
from primary cerebral cells derived from rat fetuses, demon-
strating that after immortalization with the simian virus 40
large tumor antigen, these cultured cells accumulated EPO
mRNA in an oxygen-dependent manner. They also provided
immunochemical evidence that astrocytes might represent the
EPO-producing cell population. These in vitro results further
support the notion that EPO plays an as yet undefined role in
the mammalian brain. At present, the physiological function of
EPO in brain is an open question. It is known that hypoxia
induces changes in membrane conductivity of neuronal cells
for K+, Na+, and Ca2+ ions (reviewed in refs. 36 and 37). This
effect reduces the cellular requirement for ATP and might
prevent cell damage during hypoxia. We speculate that EPO
might be involved in the regulation of membrane conductivity
during oxygen deprivation to preserve intracellular ATP. In
preliminary results, a rapid increase in intracellular Ca2+
concentration (17) and in Ca2+ flux (38) was observed after
application ofEPO to PC12 cells. Further electrophysiological
experiments are needed to elucidate the role of EPO/EPO-R
interaction in brain cells. In addition, localization of EPO
binding sites in the hippocampus, an area that is especially
vulnerable to reduced oxygen supply (39), further supports the
notion that EPO and its receptor might be involved in the
protection of cerebral cells from hypoxic damage.
In summary, expression of EPO-R mRNA in brain tissue,
localization of specific EPO binding sites in situ, and detection
of hypoxic upregulation of EPO mRNA in the brain suggest a
functional role of EPO and EPO-R in mammalian brain and
imply that EPO is a polyfunctional rather than a monofunc-
tional growth factor, like many other hematopoietic factors
that bind to receptors of the cytokine superfamily.
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